J Immunother Cancer: Efficacy and safety of IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) in the treatment of advanced melanoma

Immune checkpoint inhibitors are often used in the treatment of advanced melanoma.
For example, CTLA4 and PD1 inhibitors are commonly used
.

The combination of the two can achieve an objective response rate (ORR) of approximately 58%, but grade 3/4 adverse events have also increased significantly

Immune checkpoint inhibitors are often used in the treatment of advanced melanoma.

The study is a single-arm phase II study, and immune checkpoint inhibitors include pembrolizumab (P), nivolumab (N), or ipilimumab (I)
.

The dosage used is the approved standard dosage

The study is a single-arm phase II study, and immune checkpoint inhibitors include pembrolizumab (P), nivolumab (N), or ipilimumab (I)

The study included 131 patients, 114 (87%) patients used pembrolizumab (pembrolizumab)

research summary

research summary

In the efficacy evaluation population, ORR was 51% (including 18 CR, 27 PR), DCR was 70% (including 18 CR, 27 PR, and 17 SD), and the median DoR was 33 months; 13 previous cases The ORR of patients who received radiotherapy was 64% (including 5 cases of CR)
.

The median PFS was 12.

In the efficacy evaluation population, ORR was 51% (including 18 CR, 27 PR), DCR was 70% (including 18 CR, 27 PR, and 17 SD), and the median DoR was 33 months; 13 previous cases The ORR of patients who received radiotherapy was 64% (including 5 cases of CR)

Efficacy evaluation

Efficacy evaluation

The median time to response was 2.
79 months (2.
07, 20.
68)
.

Patients who achieved complete remission (CR) or partial remission (PR) had a durable response, with a median DOR of 30.

The median time to response was 2.

Toxicity assessment was performed in 114 patients.

Common adverse events

 Common adverse events

In summary, studies have shown that IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) has curative effect and controllable toxicity in the treatment of advanced melanoma, and it is worthy of further exploration in the future
.

In summary, studies have shown that IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) has curative effect and controllable toxicity in the treatment of advanced melanoma, and it is worthy of further exploration in the future
.

Studies have shown that IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) has curative effect and controllable toxicity in the treatment of advanced melanoma, and it is worthy of further exploration in the future

Original source:

Yousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
J Immunother Cancer.
2021 Jun;9(6):e002057.
doi: 10.
1136 /jitc-2020-002057.

Yousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
J Immunother Cancer.
2021 Jun;9(6):e002057.
doi: 10.
1136 /jitc-2020-002057.
Leave a message here